Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature

Jeroen CH van der Hilst,1,2 Michel Moutschen,3 Peter E Messiaen,1,2 Bernard R Lauwerys,4,5 Steven Vanderschueren6 1Department of Infectious diseases and Immunity, Jessa Hospital, Hasselt, 2Biomedical Research Institute, University of Hasselt, Hasselt, 3Department of Immunity and Infectious Diseases,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	van der Hilst JC, Moutschen M, Messiaen PE, Lauwerys BR, Vanderschueren S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	familial Mediterranean fever interleukin 1 amyloidosis colchicine Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/780f79871b71441488158dd9a4532e52
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:780f79871b71441488158dd9a4532e52
record_format	dspace
spelling	oai:doaj.org-article:780f79871b71441488158dd9a4532e522021-12-02T00:03:08ZEfficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature1177-5491https://doaj.org/article/780f79871b71441488158dd9a4532e522016-04-01T00:00:00Zhttps://www.dovepress.com/efficacy-of-anti-il-1-treatment-in-familial-mediterranean-fever-a-syst-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Jeroen CH van der Hilst,1,2 Michel Moutschen,3 Peter E Messiaen,1,2 Bernard R Lauwerys,4,5 Steven Vanderschueren6 1Department of Infectious diseases and Immunity, Jessa Hospital, Hasselt, 2Biomedical Research Institute, University of Hasselt, Hasselt, 3Department of Immunity and Infectious Diseases, University Hospital of Liège, Liège, 4Service de Rhumatologie, Cliniques Universitaires Saint-Luc, 5Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, 6KU Leuven, Laboratory of Clinical Infectious and Inflammatory Disorders, University Hospitals Leuven, Leuven, Belgium Introduction: In 5%–10% of patients with familial Mediterranean fever (FMF), colchicine is not effective in preventing inflammatory attacks. Another 5%–10% of patients are intolerant to effective doses of colchicine and experience serious side effects. Treatment with anti-interleukin-1 (IL-1) drugs may be an alternative for these patients, although it is not reimbursed for this indication in many countries. Methods: We systematically searched PubMed, Web of Science, and Scopus for reports of anti-IL-1 treatment in FMF patients. Results: Out of 284 potentially relevant articles, 27 eligible reports were identified and included in the data analysis. Conclusion: A complete response to therapy without a single attack during treatment was reported in 76.5% of patients on anakinra treatment and in 67.5% of patients during canakinumab treatment. In patients with established type AA amyloidosis, anti-IL-1 treatment can reverse proteinuria. Anti-IL-1 therapy seems to be a safe and effective alternative for patients with FMF who do not respond to or cannot tolerate colchicine. Keywords: familial Mediterranean fever, interleukin-1, amyloidosis, colchicinevan der Hilst JCMoutschen MMessiaen PELauwerys BRVanderschueren SDove Medical Pressarticlefamilial Mediterranean feverinterleukin 1amyloidosiscolchicineMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2016, Iss Issue 1, Pp 75-80 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	familial Mediterranean fever interleukin 1 amyloidosis colchicine Medicine (General) R5-920
spellingShingle	familial Mediterranean fever interleukin 1 amyloidosis colchicine Medicine (General) R5-920 van der Hilst JC Moutschen M Messiaen PE Lauwerys BR Vanderschueren S Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature
description	Jeroen CH van der Hilst,1,2 Michel Moutschen,3 Peter E Messiaen,1,2 Bernard R Lauwerys,4,5 Steven Vanderschueren6 1Department of Infectious diseases and Immunity, Jessa Hospital, Hasselt, 2Biomedical Research Institute, University of Hasselt, Hasselt, 3Department of Immunity and Infectious Diseases, University Hospital of Liège, Liège, 4Service de Rhumatologie, Cliniques Universitaires Saint-Luc, 5Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, 6KU Leuven, Laboratory of Clinical Infectious and Inflammatory Disorders, University Hospitals Leuven, Leuven, Belgium Introduction: In 5%–10% of patients with familial Mediterranean fever (FMF), colchicine is not effective in preventing inflammatory attacks. Another 5%–10% of patients are intolerant to effective doses of colchicine and experience serious side effects. Treatment with anti-interleukin-1 (IL-1) drugs may be an alternative for these patients, although it is not reimbursed for this indication in many countries. Methods: We systematically searched PubMed, Web of Science, and Scopus for reports of anti-IL-1 treatment in FMF patients. Results: Out of 284 potentially relevant articles, 27 eligible reports were identified and included in the data analysis. Conclusion: A complete response to therapy without a single attack during treatment was reported in 76.5% of patients on anakinra treatment and in 67.5% of patients during canakinumab treatment. In patients with established type AA amyloidosis, anti-IL-1 treatment can reverse proteinuria. Anti-IL-1 therapy seems to be a safe and effective alternative for patients with FMF who do not respond to or cannot tolerate colchicine. Keywords: familial Mediterranean fever, interleukin-1, amyloidosis, colchicine
format	article
author	van der Hilst JC Moutschen M Messiaen PE Lauwerys BR Vanderschueren S
author_facet	van der Hilst JC Moutschen M Messiaen PE Lauwerys BR Vanderschueren S
author_sort	van der Hilst JC
title	Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature
title_short	Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature
title_full	Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature
title_fullStr	Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature
title_full_unstemmed	Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature
title_sort	efficacy of anti-il-1 treatment in familial mediterranean fever: a systematic review of the literature
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/780f79871b71441488158dd9a4532e52
work_keys_str_mv	AT vanderhilstjc efficacyofantiil1treatmentinfamilialmediterraneanfeverasystematicreviewoftheliterature AT moutschenm efficacyofantiil1treatmentinfamilialmediterraneanfeverasystematicreviewoftheliterature AT messiaenpe efficacyofantiil1treatmentinfamilialmediterraneanfeverasystematicreviewoftheliterature AT lauwerysbr efficacyofantiil1treatmentinfamilialmediterraneanfeverasystematicreviewoftheliterature AT vanderschuerens efficacyofantiil1treatmentinfamilialmediterraneanfeverasystematicreviewoftheliterature
_version_	1718403993698304000

Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature

Ejemplares similares